Exhibit 99.1 For the three months ended October 31, 2025, we recorded a net loss attributable to Rafael Holdings of $9.8 million, or$0.19 per share, versus a net loss of $9.0 million, or$0.37 per share in the year ago period. The year over year increase in net loss is attributable to the consolidation of Cyclo Therapeutic's expenses following the acquisition of Cyclo in March 2025. Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results NEWARK, NJ – December 11, 2025 (GLOBE NEWSWIRE) - Rafael ...